The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

mRNA vaccines, pivotal in the fight against COVID-19, are now emerging as a promising innovation in cancer treatment. As ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

In a bid to expand its oncology program, Genprex has formed a Mesothelioma Clinical Advisory Board and reported progress in its Acclaim-1 and Acclaim-3 lung cancer gene therapy trials. The company ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...